Xeris Bio rises on upbeat 2022 results

Xeris Biopharma Holdings

08/03/2023 12:48

** Shares of drug developer Xeris Biopharma Holdings Inc
 XERS.O  rise 4.6% to $1.6 premarket 
    ** Co reports Q4 revenue of $33.14 million, above analysts'
estimates of $31.04 million - Refinitiv 
    ** Also reports Q4 net loss of $0.10 per share, compared to
analysts estimates of $0.16 loss per share -Refinitiv  
    ** Co expects 2023 net revenue in the range of $135 mln
to$165 mln v/s estimates of $152.31 mln -Refinitiv 
    ** XERS expects cash, cash equivalents, and short-term
investments between $45 mln and $65 mln by the end of 2023  
    ** Says has cash and cash equivalents of $122 mln as of Dec.
31, 2022 
    ** Up to Tuesday's close, stock fell ~33% over the past 12
months

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com;))